The Share

The Diamyd Medical share is traded on Nasdaq First North (ticker : DMYD B). ISIN code: SE0005162880.

About Nasdaq First North

Nasdaq First North is an alternative marketplace operated by an exchange within the Nasdaq Group. Companies on Nasdaq First North are not subject to the same rules as companies on the regulated main market. Instead they are subject to a less extensive set of rules and regulations adjusted to small growth companies. The risk in investing in a company on Nasdaq First North may therefore be higher than investing in a company on the main market. All companies with shares traded on Nasdaq First North have a Certified Adviser who monitors that the rules are followed. The Exchange approves the application for admission to trading.

Certified Adviser at Nasdaq First North

FNCA Sweden AB, Humlegårdsgatan 5, Box 5807, SE-102 48 Stockholm. Tel: 08-528 00 399.

Annual Report

  November 9, 2017
  Quarterly Report 3, June 27, 2018

Dear Shareholders and readers

Two weeks ago, Diamyd Medical had another drug enter clinical development phase, when the Swedish Medical Products Agency approved our GABA-based Remygen™ for clinical trials. I would like to clearly highlight the importance of having two drugs — Diamyd® and Remygen™ — in clinical development phase. Both of our clinical development drugs focus on the underlying disease mechanisms in diabetes with the goal of slowing, stopping and ultimately reversing the progression of the disease.

With two drugs in clinical development that complement and strengthen each other, the likelihood increases of making meaningful differences for those who live with diabetes.
Ulf Hannelius, President and CEO

Calendar

 Dates for financial information and other events
September 10, 2018
NLS Days
October 3, 2018
Financial statement
Financial statement 2017/2018
October 25, 2018
Annual Report
Annual Report 2017/2018
November 15, 2018
Annual General Meeting
Annual General Meeting 2017/2018
 

We are dedicated to finding a cure for autoimmune diabetes through pharmaceutical development and investments in medical and stem cell technologies

 

Ten largest shareholders as of March 29, 2018

ShareholderA SharesB SharesCapital %Votes %
Essen-Möller, Anders 2 130 186 6 110 867 14.63 36.31
Avanza Pension 6 475 951 11.50 8.58
Lindkvist, Bertil 6 160 000 10.93 8.16
Nordnet Pensionsförsäkring AB 2 080 411 3.69 2.76
Hansen, Patrik 1 300 000 2.31 1.72
Swedbank Försäkring 926 304 1.64 1.23
Ålandsbanken AB 524 433 0.93 0.69
Arandi Development AB 500 000 0.89 0.66
Konstruktions o Försäljningsaktiebolag 415 000 0.74 0.55
Relbo AB 396 292 0.70 0.52
Remaining shareholders 29 314 460 52.04 38.82
Total 2 130 186 54 203 718 100.0 100.0